Objective: To investigate and analyze the effect of gemcitabine bladder perfusion therapy on patients with bladder spasm after transurethral resection of bladder tumor. Methods: From January 2016 to December 2019, a total of 78 patients with bladder tumor who underwent transurethral resection in our hospital, were selected as the study subjects. Patients were divided into control group(39 cases) and observation group(39 cases) randomly. The control group was treated with transurethral resection of tumor, while the observation group was treated with transurethral resection followed by Gemcitabine bladder perfusion. Visual Analogue Scale(VAS) and Bladder Spasm Symptom Score(BSSS) were used to evaluate the degree of pain and the severity of bladder spasm. Results: The frequency of bladder spasm in the observation group was significantly lower than that in the control group on day 1, 3, 5 and 7 after surgery, and the duration of bladder spasm was significantly shorter than that in the control group(P<0.05);At 6 h, 12 h and 24 h after surgery, the VAS score of the observation group was significantly lower than that of control group(P<0.05);BSSS evaluation showed that both groups had different degrees of bladder spasm after surgery, but the severity of bladder spasm in the observation group was significantly lower than that in the control group(P< 0.05). Conclusion: Gemcitabine bladder perfusion therapy can relieve the pain brought by bladder spasm after transurethral resection, shorten the duration of spasm, and alleviate the symptoms of bladder spasm.